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ABSTRACT: Amylases are key enzymes in the processing of
starch in many kingdoms of life. They are important catalysts in
industrial biotechnology where they are applied in, among others,
food processing and the production of detergents. In man amylases
are the first enzymes in the digestion of starch to glucose and
arguably also the preferred target in therapeutic strategies aimed at
the treatment of type 2 diabetes patients through down-tuning
glucose assimilation. Efficient and sensitive assays that report selectively on retaining amylase activities irrespective of the nature and
complexity of the biomaterial studied are of great value both in finding new and effective human amylase inhibitors and in the
discovery of new microbial amylases with potentially advantageous features for biotechnological application. Activity-based protein
profiling (ABPP) of retaining glycosidases is inherently suited for the development of such an assay format. We here report on the
design and synthesis of 1,6-epi-cyclophellitol-based pseudodisaccharides equipped with a suite of reporter entities and their use in
ABPP of retaining amylases from human saliva, murine tissue as well as secretomes from fungi grown on starch. The activity and
efficiency of the inhibitors and probes are substantiated by extensive biochemical analysis, and the selectivity for amylases over
related retaining endoglycosidases is validated by structural studies.
■ INTRODUCTION
Retaining α-amylases, belonging to the glycoside hydrolase
(GH) 13 family (www.cazy.org),1 are starch-processing
enzymes present in plants, animals, and microorganisms.2−4
They catalyze the hydrolysis of internal α-1,4-glycosidic
linkages in starch and related polysaccharides through a two-
step Koshland double displacement mechanism (Figure S2A).
In this mechanism, the aglycon is protonated by the general
acid/base residue, followed by SN2 nucleophilic attack by the
catalytic nucleophile at the anomeric center to form a covalent
enzyme−substrate intermediate with inversion of anomeric
configuration. The covalent enzyme−substrate adduct is
subsequently hydrolyzed to yield oligosaccharide products
(for instance linear and α-1,6-branched malto-oligosacchar-
ides) with net retention of α-anomeric configuration.5
Starch is the main product of major human and animal
feedstock crops including wheat, rice, maize, tapioca, and
potato. Traditionally, large-scale starch processing, an industry
established over 100 years ago, relied on the degradation of
starch by acid hydrolysis.6,7 Amylases have gained considerable
traction as alternatives to conventional chemical starch
hydrolysis, as they are more environmentally benign, are less
energy intensive, and moreover may produce more defined
oligosaccharide products from starch polymers.8,9 Today, a
large number of α-amylases from microbial sources are
commercially available and are widely used for the production
of high glucose and fructose syrups.10,11 Another major
application of α-amylases is found in the detergent industry,
where they act at low temperatures and alkaline pH to remove
tough starch stains from clothes and porcelains under mild
conditions.12 α-Amylases are furthermore extensively em-
ployed in textile, food, paper, and biofuel industries. The α-
amylases currently applied in industrial biotechnology originate
from a limited number of fungal and bacterial strains, including
Aspergillus oryzae and Bacillus licheniformis.11,13 The microbial
world however may harbor many additional α-amylases
including ones that differ functionally in terms of activity,
substrate specificity, and resistance to (harsh) biotechnological
conditions.
In addition to their potential in biotechnological applica-
tions, α-amylases have received increased interest in the past
decades in the context of human health. In mammals, digestion
of starch by salivary and pancreatic α-amylases leads to linear
and branched malto-oligosaccharides. These are largely hydro-
lyzed to glucose by α-glucosidases located in the intestinal
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mucosa, which then enters the bloodstream by means of
facilitated diffusion. Control of postprandial glucose levels,
which has proven to be a key factor for the treatment of
diabetes and obesity,14 might be achieved by activity
modulation of starch-processing enzymes. Antidiabetic drugs
currently used in the clinic include the α-glucosidase
inhibitors,15,16 miglitol, voglibose, and acarbose, the last of
which also inhibits human pancreatic α-amylase (HPA).17,18
However, their effectiveness is offset by undesirable side
effects, including diarrhea, flatulence, and abdominal pain,
secondary effects that arise predominantly from inhibition of
intestinal α-glucosidases. Hence, selective inhibitors targeting
exclusively HPA, the first enzyme in the digestion sequence,
would be of great interest.19−24
Activity-based protein profiling (ABPP) has emerged as a
powerful strategy to obtain qualitative and quantitative activity
information on enzymes of interest in complex mixtures.25,26
ABPP is especially useful for retaining glycosidases that form a
covalent enzyme−substrate intermediate during hydrolysis. It
relies on the availability of suitable activity-based probes
(ABPs) that are generally generated from covalent and
irreversible inhibitors by equipping these with a reporter entity
(a fluorophore or biotin) or a bio-orthogonal tag. By means of
ABPP, enzyme activities can be rapidly identified and
quantified (comparative ABPP) and the effect of inhibitors
on target enzymes studied in cell extracts and living cells
(competitive ABPP). Our work on retaining glycosidase ABPP
is rooted in the known mechanism-based β-glucosidase
inhibitor cyclophellitol, isolated from Phellinus sp.27 In the
first instance we applied cyclophellitol-derived ABPs to the
study of retaining exo-acting α- and β-glycosidases.28−32 More
recently, we expanded the methodology toward retaining
endoglycosidases in our work on xylobiose-configured ABPs to
investigate endo-acting xylanases in Aspergillus secretomes.33,34
Here, we reveal the efficacy of retaining glycosidase ABPP by
the design and chemical synthesis of a panel of maltobiose epi-
cyclophellitol derived retaining α-amylase inhibitors and ABPs,
the kinetic and structural analysis of their interactions with
microbial α-amylases, and the application of these probes for
rapid detection and identification of α-amylases in fungal
secretomes, mouse tissue, and human saliva. Our work
complements a recent24 study by Withers and colleagues,
who reported a chemoenzymatic synthesis of maltobiose epi-
cyclophellitol, to which we could match our chemically derived
material and as well our structural work on α-amylase-inhibitor
complexes. Our results moreover illustrate the potential of
retaining α-amylase ABPP in the annotation of α-amylases in
complex biological samples.
■ RESULTS AND DISCUSSION
Design and Synthesis of α-Amylase Inhibitors and
Activity-Based Probes. We have previously revealed that
1,6-epi-cyclophellitol and its aziridine and cyclic sulfate
analogues (Figure 1A) are potent mechanism-based α-
glucosidase inhibitors and that their tagged versions are
effective activity-based retaining α-exoglucosidase probes.30,35
These monosaccharidic cyclitols however do not inhibit endo-
acting α-amylases, which we argued is because of the absence
of productive binding with the larger endo-glycosidase active
sites (Figure S2C). In line with this consideration, Withers and
co-workers subsequently reported that the maltose disacchar-
ide mimetic α-1,4-glucopyranosyl epi-cyclophellitol (com-
pound 1a, Figure 1B), which they prepared by enzymatic α-
glucosylation of 1,6-epi-cyclophellitol, is an effective mecha-
nism-based, covalent, and irreversible HPA inhibitor.24
Crystallographic analysis of an HPA−inhibitor complex points
to the O4′ of the nonreducing end sugar, which may simply be
alkylated to block potential exoglycosidase action as a
promising site for orthogonal functionalization (as in 1b) to
allow introduction of a reporter entity (a fluorophore or biotin,
as in 1c and 1d). Alternatively and in line with our previous33
work on xylanase ABPs, we envisaged the design of maltose-
configured cyclophellitol aziridines bearing the reporter tag on
the aziridine nitrogen, either with or without an O4′ cap
(compounds 2a−2c, Figure 1B). Finally and in line with our
previous results on 1,6-epi-cyclophellitol cyclosulfate being a
potent and selective retaining α-exoglucosidase inhibitor,30,35
we decided to produce the corresponding maltose cyclosulfate
(compound 3a, Figure 1B) as well with the aim to investigate
whether this Michaelis complex emulating inhibitor would also
act on amylases.
We have recently reported the synthesis of xylobiose-
cyclophellitols via the direct glycosylation of xylo-cyclophellitol
(aziridine) acceptors.33 This route however appeared not
feasible for the construction of compounds 1a−d since the
epoxide functionality in partially protected 1,6-epi-cyclo-
phellitols proved unstable toward stoichiometric amounts of
Lewis acid under the conditions required to effect formation of
α-1,4-glycosidic bonds using contemporary glycosylation
conditions. Alternatively, cyclohexene 5 was found to readily
undergo glycosylation with imidate donor 4a under N,N-
dimethylformamide (DMF) and trifluoromethanesulfonic acid
(TfOH) activating conditions, affording pseudodisaccharide 6a
in good yield.36 Selective deprotection of the 4-methoxybenzyl
group in 6a followed by epoxidation afforded an inseparable
mixture of α/β-epoxides in a 1:3 ratio, which were silylated and
separated by silica gel column chromatography to yield pure 8a
and 9a. Desilylation and global debenzylation of 8a by
Pearlman’s catalyst hydrogenation gave maltobiose epi-cyclo-
phellitol 1a, of which all analytical and spectroscopical data
proved to match those of the chemoenzymatically produced
compound.24 The epoxide in 9a was converted to aziridine 14a
by treatment with sodium azide followed by a Staudinger-type
Figure 1. Design of mechanism-based retaining α-glucosidase
inhibitors and ABPs: (A) structures of retaining α-exoglucosidase
inhibitors; (B) structures of retaining α-endoglucosidase inhibitors
and ABPs, which are subject of the here-described studies.
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ring closure. Alkylation and global deprotection of 14a under
Birch conditions afforded alkyl-aziridine 2a, which was
equipped with a Cy5 fluorophore to produce ABP 2b (Scheme
1).
Our previous studies on endo-xylanases revealed that the
xylobiose-cyclophellitol aziridine probe was susceptible to
hydrolysis by exo-xylosidases present in Aspergillus secre-
tomes.33 Thus, we hypothesized that “capping” the O4′
position of maltobiose epi-cyclophellitol azirines with an ethyl
group would prevent cleavage by exo-acting α-glucosidases in
complex biological samples. This was achieved by using O4
ethyl capped thiophenyl donor 4b for glycosylation with
acceptor 5 under N-iodosuccinimide (NIS)/DMF/TfOH
catalysis, giving 4′-ethyl pseudodisaccharide 6b in good yield.
Following the same route as for 2a, 4′-ethyl capped maltobiose
epi-cyclophellitol aziridine 16 could be readily obtained from
intermediate 9b, which was equipped with a Cy5 fluorophore
to produce ABP 2c. We constructed epoxide-based ABPs by
using thiophenyl donor 4c, where the azidooctyl group was
introduced in an early stage for later installation of reporter
entities and also to prevent exo-glycosidase processing.
Following the established route, epoxide 1b was obtained
after desilylation, azide reduction, and debenzylation of 8c.
Following coupling with a Cy5 fluorophore or biotin moiety,
ABPs 1c and 1d were obtained, respectively.
The same strategy was also applied to construct maltobiose
epi-cyclophellitol cyclosulfate 3a. Carbonate acceptor 17 was
readily glycosylated with donor 4a under TfOH/DMF
conditions, giving pseudodisaccharide 18 in moderate yield.
Treatment of 18 with sodium methoxide gave diol 19.
Generation of the cyclosulfite using thionyl chloride and
subsequent oxidation gave perbenzylated cyclosulfate 20, the
benzyl ethers of which were removed by Pearlman’s catalyst
hydrogenation to afford inhibitor 3a.
Kinetic Studies for Time-Dependent Inhibition of
Aspergillus oryzae α-Amylase by Maltobiose Inhibitors.
To assess the potency of the synthesized maltobiose epi-
cyclophellitols, we monitored the time-dependent inhibition of
Aspergillus oryzae α-amylase (hereafter termed as Taka-
amylase). Taka-amylase, one of the earliest amylases to be
characterized and used commercially,37,38 is a retaining α-
amylase belonging to the GH13 subfamily 1. This enzyme uses
Scheme 1. Synthesis of the Inhibitors and ABPs Subject of the Here-Described Studiesa
aReagents and conditions. (a) For 6a and 18: 4a, TfOH (1.5 equiv), DMF, DCM, 4 Å molecular sieves, −20 to 0 °C, 6a 96%, 18 57%. For 6b: 4b,
NIS, TfOH (1.5 equiv), DMF, DCM, 4 Å molecular sieves, 0 °C, 88%. For 6c: 4c, NIS, TfOH (1.5 equiv), DMF, DCM, 4 Å molecular sieves, 0 °C,
87%. (b) DDQ, DCM/H2O (19/1), rt, 7a 80%, 7b 74%, 7c 71%; (c) (i) mCPBA, DCM, 0 °C to rt; (ii) TBSCl, DMAP, imidazole, DCM, rt, 8a
20%, 9a 58%, 8b 21%, 9b 65%, 8c 22%, 9c 63%; (d) TBAF, THF, rt, 10a 90%, 10b 87%, 12a 91%, 12b 88%; (e) Pd(OH)2/C, H2, MeOH/H2O/
dioxane (2/1/2), rt, 1a 100%, 3a 89%; (f) polymer-bound PPh3, MeCN, H2O, 70 °C, 79%; (g) Pd(OH)2/C, H2, HOAc,
tBuOH/H2O/dioxane
(1/2/1), rt, 91%; (h) Cy5-OSu or biotin-OSu, DIPEA, DMF, rt, 1c 33%, 1d 16%, 2b 10%, 2c 17%; (i) BnBr, NaH, TBAI, DMF, 0 °C to rt, 13a
82%, 13b 75%; (j) (i) NaN3, LiClO4, DMF, 100 °C; (ii) polymer-bound PPh3, MeCN, 60 °C, 14a 48%, 14b 42%; (k) 8-
azidooctyltrifluoromethanesulfonate, DIPEA, DCM, 0 °C to rt, 15a 90%, 15b 88%; (l) Na, NH3 (liq.),
tBuOH, THF, −60 °C, 2a 79%, 16
94%; (m) NaOMe, DCM/MeOH (1/1), rt, 93%; (n) (i) SOCl2, TEA, DCM, 0 °C; (ii) RuCl3·3H2O, NaIO4, EtOAc/ACN/H2O (2/2/1), 0 °C,
58%.
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a pair of catalytic active site residues (Asp206 as a nucleophile
and Glu230 as the acid/base) to cleave amylose chains and
requires several subsites to be occupied to catalyze hydrolysis
at meaningful rates.39
To assess time-dependent inhibition, the hydrolysis of 2-
chloro-4-nitrophenyl maltotrioside (CNP-M3) by Taka-
amylase was measured after preincubation with 2 mM of
inhibitors 1a, 1b, 2a, and 3a. All four inhibitors displayed a
time-dependent inhibition of Taka-amylase; however the rates
of inhibition varied greatly (Figure 2). Both the epi-
cyclophellitol epoxide 1a and aziridine 2a had slow rates of
inactivation, with rate constants of 0.0061 ± 0.0002 min−1 and
0.005 ± 0.002 min−1, respectively. The rate constant for the
inactivation by 1a is somewhat higher than was previously
observed for its inhibition of HPA, determined to be 0.001
min−1 at a higher concentration of inhibitor (3.6 mM).24 It is
somewhat surprising that the aziridine had a rate of inhibition
slightly worse than that of the epoxide, as our previous work
has demonstrated aziridine based inhibitors to be more potent
for α-glucosidases.30 We speculate that N-alkylation of the
aziridine may reduce the initial binding of inhibitor 2a,
consequently reducing inactivation rates. Inhibition by the
cyclosulfate inhibitor 3a was 4- to 5-fold faster (rate constant =
0.0250 ± 0.0009 min−1) when compared to 1a or 2a. This
observation agrees well with our previous work, which showed
that the monosaccharide epi-cyclophellitol cyclosulfate was
indeed the most potent cyclophellitol type inhibitor of
recombinant lysosomal acid α-glucosidase.35 Surprisingly, 4′-
alkylamine 1b proved to be the most effective inhibitor tested,
with an inhibition rate constant that was nearly 10 times that of
the untagged 1a (rate constant = 0.057 ± 0.003 min−1). This
suggests that initial binding of 1b is aided by interactions
between the −3 subsite and the 4′-alkylamine present, which
in turn increases the rate of inhibition. Previous kinetic analysis
of Taka-amylase catalytic rates has shown dramatic rate
increases for the hydrolysis of a maltotetrasaccharide over a
maltotrioside,39 highlighting the importance of binding in the
−3 position with a natural substrate.
Structural Analysis of Inhibitor−Enzyme Complexes.
We next sought to use X-ray crystallography to further
understand the binding of inhibitors 1a, 1b, 2a, and 3a to the
active site of Taka-amylase. All four inhibitors formed covalent
complexes with Taka-amylase, solved with resolution between
1.67 and 1.35 Å, and were covalently linked to the enzyme
through the catalytic nucleophile Asp206 (Figure 3). The slow
reaction rates necessitated prolonged incubation of the
inhibitors with preformed crystals. The epi-cyclophellitol
epoxides were soaked for 3 days. At this stage 1a reached
80% active site occupancy, while 1b had complete occupancy,
reflective of its increased rate constant of inhibition when
compared to 1a. After a week-long soak with 2a Taka-amylase
crystals had approximately 70% inhibitor occupancy; thus soak
length for this compound was further extended to 1 month
after which complete occupancy was observed. The soak with
3a was also extended to 1 month to allow for complete active
site occupancy.
The crystal structure of 1a bound to the active site
nucleophile (Asp206) showed the cyclitol moiety to adopt a
4C1 chair conformation, which is also observed for 1b and 3a.
This conformation matches that observed for the −1 sugar by
Caner et al.24 for the binding of enzymatically synthesized 1a
to HPA and the conformation of an in situ generated 5-fluoro-
idose trisaccharide, also to HPA.23 Although a detailed
computational analysis of the conformational itineraries for a
GH13 α-amylase has yet to be done, a detailed analysis of a
homologous GH13 amylosucrase from Neisseria polysaccharea




4C1 trajectory for the glycosylation step, consistent with the
observed conformation of the inhibitor bound in the −1
position. The nucleophile, Asp206, in the 1a complex structure
is present in two conformations, one minor unbound
conformation which aligns with the uncomplexed form (PDB
code 6YQ7) and the other rotated approximately 120° from
the uncomplexed orientation that we ascribe to the
conformation present in the covalently inhibited enzyme
(Figure 3, panel A, PDB code 6YQ9). This second
conformation is also seen for the 1b complex which is at full
occupancy. Bound 1a also forms nine direct hydrogen bonds
with Taka-amylase (with His122, Arg204, Thr207, His296, and
Asp297 in the −1 subsite and Trp83, Asp340, and Arg344 in
the −2 subsite), replicating those seen in the structure of a
complex between Taka-amylase and acarbose (PDB code
7TAA), with the exception of the hydrogen bond between the
6-OH of 1a and Thr207, and the lack of an H-bond with the
catalytic nucleophile that is observed for acarbose.41
The structure of 4′-alkylamine epi-cyclophellitol 1b bound in
the active site (Figure 3, panel B, PDB code 6YQC) maintains
an identical hydrogen bonding network to that seen in the
complex with 1a, the only difference being the complete
occupancy of the inhibitor, resulting in the absence of an
unbound Asp206 conformer and the presence of an alkyl tail.
The 4′ tail of 1b can only be modeled to the sixth carbon
(away from the maltose core) indicating that the terminal
amine may form multiple interactions in the −3 subsite. The
portion of the alkyl tail that could be modeled with confidence
is appropriately positioned to form a C−H/π hydrogen bond
through the second carbon which is 3.9 Å away from Tyr75.
This interaction may in part be responsible for better binding
of 1b to Taka-amylase and the resulting increased rate of
inhibition.
The structure of the epi-cyclophellitol cyclosulfate 3a
complex has many similarities with complexes of the epoxide
inhibitors 1a and 1b (Figure 3, panel C, PDB code 6YQB).
Figure 2. Time-dependent inactivation of Taka-amylase. Residual
activity of Taka-amylase incubated with 2 mM of either 1a (◐), 1b
(○), 2a (⊗), or 3a (●) was assayed over time and fit to an
exponential decay curve.
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The cyclitol is covalently attached to Asp206, again rotated
approximately 120° from the unreacted enzyme, and is in a 4C1
conformation. The −2 sugar is positioned exactly as for 1a,
however the presence of an exocyclic sulfur at the 6 position
has resulted in Thr207 being positioned within hydrogen
bonding distance to the O6 that forms the sulfate ester. The
sulfate group is also positioned within hydrogen bonding
distance to the acid base residue, Glu230; however this residue
appears in two different conformations in the structure.
Binding of 2a to Taka-amylase is strikingly dissimilar to the
other three inhibitor complexes (Figure 3, panel D, PDB code
6YQA). The inhibitor is again covalently bound to Asp206;
however the nucleophile is rotated nearly 180° when compared
to the other three complexes such that the nonbonded δO is
positioned above the “β” face of the bound cyclitol ring rather
than below it. The hydrogen bonds between the inhibitor and
the enzyme −1 subsite are also altered, with the cyclitol
methoxy alcohol rotated to form a hydrogen bond with
Thr207 (instead of His122), and the C6 nitrogen forms a
hydrogen bond with the acid/base residue (Glu230).
Furthermore, the reacted cyclitol, rather than 4C1, is in an
unprecedented E3 conformation, the emergence of which we
attribute to the presence of the alkyl-chain. We have observed
that cyclophellitol aziridines with N-alkylation are generally
well accepted in both exo-acting enzymes as these often have
open + subsites28−32 and endo-acting enzymes that target β-
linkages,33 which typically contain long, tunnel, or groove-like
active sites. The active site of Taka-amylase, conversely, is a V-
shaped surface depression with a severe angle between the −1
and +1 sugar binding sites; this in turn constrains the
conformation of the aziridine alkylation and the conformation
of the cyclitol ring.
In Vitro Labeling of Recombinant Human Saliva α-
Amylase with ABPs 1c, 2b, and 2c. With the fluorescent
Figure 3. Covalent inhibition of Taka-amylase with glycosylated cyclophellitols. Crystal structures are shown between Taka-amylase and each of 1a
(A), 1b (B), 3a (C), and 2a (D). Electron density (2Fo − Fc) is shown for both the ligand and the catalytic nucleophile (Asp206) as a blue mesh
contoured at 1.5σ (1a = 0.59 e−/Å3, 1b = 0.61 e−/Å3, 2a = 0.46 e−/Å3, 3a = 0.54 e−/Å3). The polypeptide is shown in cartoon form with active site
residues shown as sticks. Apparent hydrogen bonding interactions are shown as dotted black lines. Active-site residue Arg204 is omitted for clarity.
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ABPs 1c, 2b, and 2c in hand, we first investigated their labeling
efficiency and specificity toward recombinant human saliva α-
amylase (type XIII-A, HSA). Kinetic analysis for inactivation of
Taka-amylase revealed the parent inhibitors 1a, 1b, and 2a as
slow enzyme binders. Thus, recombinant α-amylase was
incubated with ABPs 1c, 2b, or 2c at two quite high
concentrations (100 μM or 10 μM, 1 h, 37 °C, pH 7). As
shown in Figure 4A, HSA was effectively labeled by epoxide-
based ABP 1c, while the labeling potency of aziridine-based
ABPs 2b and 2c was dramatically reduced, and only very weak
bands were observed even at 100 μM probe concentrations. In
accordance with that of kinetic studies, the epoxide inhibitor
1b is much more potent than aziridine inhibitor 2a. This
observation is supported by the X-ray structure analysis of
inhibitor−enzyme complexes, which indicates that interactions
between the −3 subsite in α-amylase active sites and the O4′
substituent may contribute to the initial binding of 1b and the
resulting increased inhibition potency while the alkylation of
aziridine warhead in 2a is not preferred during enzyme
binding.
Activity-Based Protein Profiling of Retaining α-
Amylases in Complex Biological Samples. As the next
research objective, we attempted to visualize α-amylases in
concentrated human saliva and lysates from mouse pancreas
and salivary gland with ABP 1c. As shown in Figure 4B, ABP
1c labeled a distinct band at ∼57 kDa, corresponding to the
molecular weight of HSA.42 The same band was also observed
in mouse pancreas lysates where significant labeling appeared
at 25 μM (2 h, 37 °C, pH 7), while at higher probe
concentrations background fluorescence was observed. Inter-
estingly, labeling in mouse salivary gland lysates with 1c
showed two clear bands, not only the one at ∼57 kDa but also
a slightly stronger band at ∼70 kDa. Next, the pH dependence
of labeling was determined (Figure 4C). ABP 1c exhibits a
similar pH-dependent activity toward α-amylase (at the time
unknown ∼57 kDa band) in these three biological samples,
and the optimal pH for labeling is determined at 5.0, different
from the reported neutral pH optimum in HPA21 and HSA42
activity. Of note, in mouse salivary gland lysates, the band at
∼70 kDa only appeared following labeling at pH ranging from
6.0 to 8.0 with optimal labeling observed at pH 7.5.
Additionally, the efficiency and the rate of labeling of α-
amylase were further investigated under optimal pH 5.0
(Figure 4D and Figure 4E). In these three samples, α-amylase
(the ∼57 kDa band) was selectively labeled by 1c in a
concentration- and time-dependent manner, consistent with
the irreversible inhibition mechanism one would expect for the
maltose cyclophellitols.
Figure 4. (A) Fluorescent labeling of recombinant human saliva α-amylase (type XIII-A) with ABPs 1c, 2b, and 2c at pH 7 after 1 h incubation at
37 °C. (B) Fluorescent labeling of concentrated human saliva, mouse pancreas, and salivary gland lysates (55 μg total protein) with different
concentrations of ABP 1c (pH 7.0, 37 °C). (C) pH-dependent labeling with ABP 1c in complex biological samples. The optimal pH is
approximately 5.0 in these three samples. (D) Detection limit of α-amylase in complex biological samples labeled with ABP 1c (pH 5.0, 37 °C). (E)
Time-dependent labeling of α-amylase in complex biological samples with ABP 1c (pH 5.0, 37 °C). (F) Competitive ABPP on amylases in extracts
from human saliva (HS), mouse pancreas (MP), and mouse salivary gland (MSG), offset against Western blot detection of amylase abundance
using an anti-amylase antibody.
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Having established that amylase activities could be visualized
in extracts from human saliva, murine pancreas, and murine
salivary glands, competitive ABPP (cABPP) experiments were
performed to see whether these activities could be negated by
inclusion of a nontagged inhibitor. Preincubation of biological
samples with inhibitor 1d followed by labeling with Cy5 ABP
1c resulted in a decrease of fluorescent signals similar to
denaturation of the samples with 2% SDS (Figure 4F). After
fluorescent imaging, proteins were transferred to a poly-
vinylidene fluoride (PVDF) membrane for Western blot
analysis with an anti-amylase antibody. The observed
fluorescent bands and chemiluminescence bands match well
where no inhibitor is included, with the chemiluminescence
bands remaining equal in intensity where the ABP signal
decreases in an inhibitor-dependent fashion, confirming that
ABP 1c labeled amylase. cABPP assays were also performed
with inhibitors 1a and 1b in human saliva (Figure S5).
Compared with 1d, the inhibition potency of these two was
reduced and only minor competition was observed with
“untagged” 1a at the highest concentration applied (100 μM),
further indicating that alkylation of the O4′ position of the
epoxide-based inhibitor may improve its inhibition potency.
ABPP of Fungal Secretomes. The probes developed
herein can also be applied to monitor the production of
amylases by biotechnologically relevant fungi. Secretomes from
the saprophytic ascomycete Aspergillus nidulans grown on
various starches have previously been shown to contain a
complex mixture of amylases, glucosidases, and oxidative
enzymes.43 We performed ABPP of secretomes from a time
course of A. nidulans strain FGSC A4 growth in minimal media
supplemented with 1% wheat starch as a carbon source.
Secretome samples were taken daily over a 5-day period, and
the fluorescent Cy5 ABP 1c was incubated with these
secretome samples to reveal a complex pattern of fluorescent
bands that could first be detected starting by day 3. The
intensity of amylase bands increased after day 3 with a
maximum intensity at day 5 (Figure 5C).
Conventional industrial starch hydrolysis relies on enzymes
that are both thermostable and acid tolerant.44,45 Both of these
metrics can be measured directly from the secretome using
ABPP, capturing these parameters in the native enzyme
environment. Labeling of the day 5 secretome in the presence
of McIlvaine buffers at pH between 3.0 and 8.0 revealed pH
dependent labeling patterns (Figure 5A). The most intense
band (observed at ∼66 kDa) was labeled between pH 4.0 and
pH 7.0, while the bands appearing at ∼52 and ∼48 kDa were
constrained to labeling between 4.0 and 5.5 and 5.0−7.0,
respectively. We next assessed the temperature-dependent
labeling of the day 5 A. nidulans secretome at pH 5.0 and at
temperatures between 25 and 55 °C (Figure 5B). Within this
range the bands at ∼66, ∼52, and ∼48 kDa all showed
temperature dependent labeling, with labeling efficiency
decreased above 37 °C, presumably due to denaturation of
the corresponding proteins at this temperature. Conversely the
bands at ∼58 kDa and ∼44 kDa remained present at the
highest temperature tested.
We next used cABPP to show the sensitivity of enzyme
labeling to both competitive and covalent inhibitors (Figure
5D,E). As mentioned above, cABPP allows for the
identification of active enzyme inhibitors, without the need
for purification and even if the identity of the active enzyme is
unknown.46,47 Preincubation of secretomes for 30 min with
either acarbose or 3a prior to labeling with ABP 1c resulted in
decreased labeling of specific bands in a concentration
dependent manner. Enzyme bands at ∼66, ∼58, ∼52, and
∼48 kDa were all inhibited by either acarbose or 3a, while the
band at 44 kDa appeared to be insensitive to these α-amylase
inhibitors.
Identification of ABP Labeled Bands. To further
determine the specificity of the developed ABPs, we have
analyzed the ABP-labeled proteins in human saliva sample. For
this purpose, we incubated human saliva sample with
biotinylated ABP 1d, a no probe control (DMSO only), or a
competitor-inhibited control (first treatment with 1b). ABP
Figure 5. (A) Fluorescent labeling of day 5 A. nidulans secretome with ABP 1c at pH 3−8 after incubation for 1 h at 37 °C. (B) Temperature
dependent labeling of day 5 A. nidulans secretome with ABP 1c after incubation at pH 5.0 for 1 h at 25−55 °C. (C) Fluorescent labeling of day 1−5
A. nidulans secretomes with ABP 1c at pH 5.0 after incubation for 1 h at 37 °C. (D) Competitive ABPP of day 5 A. nidulans secretome with
acarbose. The secretome was preincubated with acarbose at varying concentrations (30 min, pH 5.0, 37 °C) prior to labeling with ABP 1c (67.5
μM, 1 h, pH 5.0, 37 °C). (E) Competitive ABPP of day 5 A. nidulans secretome with 3a. The secretome was preincubated with 3a at varying
concentrations (30 min, pH 5.0, 37 °C) prior to labeling with ABP 1c (67.5 μM, 1 h, pH 5.0, 37 °C).
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1d-labeled proteins were enriched by using magnetic
streptavidin beads. After on-bead tryptic digestion, the
resulting peptides were analyzed by LC−MS/MS and matched
against the human UniProt database, using the Mascot search
engine as previously described.48 As expected, AMY1A
(P04745) was clearly abundant in the ABP 1d pulldown
experiment (Table S2). Other proteins with high scores were
background proteins such as enolase standard and keratin
contaminations. Pretreatment of the saliva sample with
inhibitor 1b caused a significant loss of AMY1A peptide
abundance, and almost no AMY1A was found in the untreated
control. These results demonstrate AMY1A in human saliva
sample can be selectively labeled and identified via biotinylated
ABP 1d.
On the basis of the known content of A. nidulans
secretome,43 we tentatively assigned the most prominent
∼66 kDa band labeled with 1c as the mature form of α-amylase
AmyB (ANIA_03402); see Table S4 for list of mature α-
amylase molecular masses. The two minor bands at ∼52 and
∼48 kDa were also tentatively assigned as AmyA
(ANIA_03388) and AmyF (ANIA_0201) α-amylases, respec-
tively. As the wheat starch grown secretome of A. nidulans only
contains three amylases,43 the final two minor bands could not
be confidently assigned. We however speculate that these are
proteins that are highly abundant in the secretome.
To identify the labeled enzymes in the A. nidulans
secretome, we also performed an activity-based protein
pulldown. The day 5 secretome was treated with either the
biotinylated ABP 1d or an equivalent volume of DMSO, and
then a pulldown was performed using streptavidin beads,
followed by an on bead tryptic digest and LC−MS/MS
analysis. All three amylases from the A. nidulans secretome
(AmyA, AmyF, and AmyB) were detected at elevated levels in
the probe 1d-treated samples relative to the negative control
and total secretome, confirming our initial assignment of the
major and two minor bands observed by in-gel fluorescence
(Table S3). We also detected ChiB, an endochitanase, and
AgdB, an α-glucosidase, both of which are highly abundant in
the secretome (Table S3). The molecular weights of the
detected amylases match well with the labeled bands seen from
ABPP with probe 1c. Furthermore, these results suggest the
identities of the minor bands seen at 44 and 58 kDa may
belong respectively to CbiB and AgdB, the former, which is
proteolytically processed from its 108 kDa form to a
heterodimer with the catalytic protomer, having a 58 kDa
molecular weight.49
■ CONCLUSION
We have synthesized a panel of maltobiose-configured epi-
cyclophellitol derivatives as mechanism-based covalent inhib-
itors and ABPs for retaining α-amylases. Kinetic studies of the
inhibition of Taka-amylase revealed that the cyclosulfate
warhead (3a) is the most potent, compared with its epoxide
and aziridine counterparts (1a and 2a). As well, alkylation of
O4′ of the nonreducing end sugar in 1a led to compound 1b
that inhibits α-amylase up to 10-fold more potently than the
parent compound. Compound conformations can strongly
influence the inhibitory potencies and selectivities of cyclo-
phellitol analogues. Our X-ray studies have shown that both
epoxide and cyclosulfate-based inhibitors bind to the active site
nucleophilic residue of Taka-amylase in a 4C1 chair
conformation, while the structure of aziridine 2a complex
was found in an unprecedented E3 conformation, likely due to
the presence of the aziridine alkyl-chain, which might account
for its lower potency. The inability of fluorescent ABPs 2b and
2c to modify recombinant human saliva α-amylase further
indicated that substituted aziridines are not accepted by the
tested amylases. In contrast, epoxide-based ABP 1c selectively
labels α-amylases in human saliva and mice tissue in a
concentration- and time-dependent manner, with optimum
labeling at pH 5.0. In addition, it can also effectively detect α-
amylases in fungal secretomes and allow easy readout of pH
and temperature dependence and susceptibility to inhibitors.
Looking ahead, we speculate that installation of reporter
entities at O4′ of the nonreducing end sugar of cyclosulfate-
based inhibitor 3a would yield more potent ABPs based on
kinetic and crystallographic studies. In conclusion, our
maltobiose epi-cyclophellitol ABPs allow activity-based profil-
ing of α-amylases in complex biological samples and may find
use in the discovery of new and effective human amylase
inhibitors that may have potential as therapeutic reagents for
the treatment of type 2 diabetes and in the discovery of new




The Supporting Information is available free of charge on the
ACS Publications Web site at DOI: (PDF) (XLSX) The
Supporting Information is available free of charge at https://
pubs.acs.org/doi/10.1021/jacs.0c13059.
Experimental data and procedures, crystallographic data,
and synthesis (PDF)
Proteomics data (XLSX)
Spectral counts and raw abundance (XLSX)
■ AUTHOR INFORMATION
Corresponding Authors
Gideon J. Davies − Department of Chemistry, York Structural
Biology Laboratory, University of York, York YO10 5DD,
United Kingdom; orcid.org/0000-0002-7343-776X;
Email: gideon.davies@york.ac.uk
Herman S. Overkleeft − Department of Bioorganic Synthesis,




Yurong Chen − Department of Bioorganic Synthesis, Leiden
University, 2333 CC Leiden, The Netherlands; orcid.org/
0000-0001-5358-2989
Zachary Armstrong − Department of Chemistry, York
Structural Biology Laboratory, University of York, York
YO10 5DD, United Kingdom; orcid.org/0000-0002-
4086-2946
Marta Artola − Department of Bioorganic Synthesis and
Department of Medical Biochemistry, Leiden Institute of
Chemistry, Leiden University, 2333 CC Leiden, The
Netherlands; orcid.org/0000-0002-3051-3902
Bogdan I. Florea − Department of Bioorganic Synthesis,
Leiden University, 2333 CC Leiden, The Netherlands;
orcid.org/0000-0001-7114-2266
Chi-Lin Kuo − Department of Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, 2333 CC Leiden,
The Netherlands; orcid.org/0000-0003-3748-5008
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c13059
J. Am. Chem. Soc. XXXX, XXX, XXX−XXX
H
Casper de Boer − Department of Bioorganic Synthesis, Leiden
University, 2333 CC Leiden, The Netherlands; orcid.org/
0000-0002-0869-6060
Mikkel S. Rasmussen − Department of Biotechnology and
Biomedicine, Technical University of Denmark, 2800 Kgs.
Lyngby, Denmark
Maher Abou Hachem − Department of Biotechnology and
Biomedicine, Technical University of Denmark, 2800 Kgs.
Lyngby, Denmark; orcid.org/0000-0001-8250-1842
Gijsbert A. van der Marel − Department of Bioorganic
Synthesis, Leiden University, 2333 CC Leiden, The
Netherlands
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Marel, G. A.; Aerts, J. M.; Overkleeft, H. S. Potent and selective
activity-based probes for GH27 human retaining alpha-galactosidases.
J. Am. Chem. Soc. 2014, 136 (33), 11622−11625.
(30) Jiang, J.; Kuo, C. L.; Wu, L.; Franke, C.; Kallemeijn, W. W.;
Florea, B. I.; van Meel, E.; van der Marel, G. A.; Codeé, J. D.; Boot, R.
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Florea, B. I.; Jiang, J.; Reijngoud, J.; Ram, A. F. J.; van Wezel, G. P.;
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